Chemotherapy-Induced Nausea and Vomiting Pipeline 2025

According to DelveInsight's evaluation, the worldwide Chemotherapy-Induced Nausea and Vomiting pipeline features 4+ major companies actively advancing 6+ therapies for treating Chemotherapy-Induced Nausea and Vomiting. This includes an analysis of clinical trials, therapeutic approaches, mechanisms of action, administration methods, and developmental progress.

The Chemotherapy-Induced Nausea and Vomiting Pipeline report includes a thorough commercial and clinical evaluation of pipeline products from the preclinical stage through to marketed status. It also provides detailed descriptions of each drug, covering its mechanism of action, clinical studies, NDA approvals (if applicable), and development activities such as technology, partnerships, mergers and acquisitions, funding, designations, and other relevant product details.

"Chemotherapy-Induced Nausea and Vomiting Pipeline Insight, 2025" report by DelveInsight delivers extensive insights into the current clinical development landscape and growth opportunities in the Chemotherapy-Induced Nausea and Vomiting Market.

Key highlights from the Chemotherapy-Induced Nausea and Vomiting Pipeline Report: https://www.delveinsight.com/sample-request/chemotherapy-induced-nausea-and-vomiting-pipeline-insight?utm_source=sites&utm_medium=promotion&utm_campaign=kkpr

• Organizations worldwide are actively pursuing innovative Chemotherapy-Induced Nausea and Vomiting treatments, achieving notable progress in recent years.

• Key players in the Chemotherapy-Induced Nausea and Vomiting treatment sector include RedHill Biopharma, Acacia Pharma, Simon Williamson Clinic, Xiamen LP Pharmaceutical, Helsinn Healthcare SA, Heron Therapeutics, and others, all developing solutions for Chemotherapy-Induced Nausea and Vomiting.

• Promising Chemotherapy-Induced Nausea and Vomiting therapies at various clinical trial stages, such as RHB-102, APD403, Akynzeo, IV Palonosetron 0.25 mg, NEPA (300mg netupitant/0.5mg palonosetron), SUSTOL, and others, are anticipated to significantly influence the Chemotherapy-Induced Nausea and Vomiting market soon.

• In November 2025, Shilpa Medicare Limited (BSE: 530549) (NSE: SHILPAMED) disclosed the successful conclusion of its fourth intricate clinical initiative, SMLINJ011, with encouraging topline Phase 3 outcomes for OERISTM (Ondansetron Extended-Release Injection). This novel formulation aims to improve the management of chemotherapy-induced nausea and vomiting (CINV). This milestone underscores Shilpa's growing expertise in specialized drug-delivery technologies and oncology supportive-care treatments, reflecting its commitment to patient-oriented advancements.

• In July 2025, Incorporating 5 mg of olanzapine (Zyprexa) into a three-drug anti-nausea regimen—including an NK-1 receptor blocker, palonosetron (Aloxi), and dexamethasone—demonstrated markedly better overall antiemetic results in breast cancer patients receiving anthracycline plus cyclophosphamide chemotherapy versus placebo, as per a Phase 3 study (jRCT1031200134) featured in Lancet Oncology.

Chemotherapy-Induced Nausea and Vomiting Overview
Chemotherapy-Induced Nausea and Vomiting (CINV) is a frequent adverse reaction in cancer patients receiving chemotherapy. It involves sensations of nausea and the impulse to vomit due to chemotherapy agents impacting the digestive tract and central nervous system.

Obtain a Free Sample PDF Report for deeper insights into Chemotherapy-Induced https://www.delveinsight.com/sample-request/chemotherapy-induced-nausea-and-vomiting-pipeline-insight?utm_source=sites&utm_medium=promotion&utm_campaign=kkpr

Emerging Chemotherapy-Induced Nausea and Vomiting Drugs in Various Clinical Development Stages Include:

• RHB-102: RedHill Biopharma

• APD403: Acacia Pharma

• Akynzeo: Simon Williamson Clinic

• IV Palonosetron 0.25 mg: Xiamen LP Pharmaceutical

• NEPA (300mg netupitant/0.5mg palonosetron): Helsinn Healthcare SA

• SUSTOL: Heron Therapeutics

Chemotherapy-Induced Nausea and Vomiting Route of Administration
The Chemotherapy-Induced Nausea and Vomiting pipeline report evaluates therapies based on administration routes. Products are grouped into categories like:

• Oral

• Intravenous

• Subcutaneous

• Parenteral

• Topical

Chemotherapy-Induced Nausea and Vomiting Molecule Type
Chemotherapy-Induced Nausea and Vomiting products are classified by molecule types, including:

• Recombinant fusion proteins

• Small molecule

• Monoclonal antibody

• Peptide

• Polymer

• Gene therapy

Chemotherapy-Induced Nausea and Vomiting Pipeline Therapeutics Assessment

• Chemotherapy-Induced Nausea and Vomiting Evaluation by Product Type

• Chemotherapy-Induced Nausea and Vomiting By Stage and Product Type

• Chemotherapy-Induced Nausea and Vomiting Evaluation by Route of Administration

• Chemotherapy-Induced Nausea and Vomiting By Stage and Route of Administration

• Chemotherapy-Induced Nausea and Vomiting Evaluation by Molecule Type

• Chemotherapy-Induced Nausea and Vomiting by Stage and Molecule Type

DelveInsight's Chemotherapy-Induced Nausea and Vomiting Report encompasses approximately 6+ products across clinical phases, such as:

• Late-stage products (Phase III)

• Mid-stage products (Phase II)

• Early-stage products (Phase I)

• Pre-clinical and Discovery stage candidates

• Discontinued & Inactive candidates

• Route of Administration

Additional details on Chemotherapy-Induced Nausea and Vomiting products are included in the report. Download the Chemotherapy-Induced Nausea and Vomiting pipeline report to explore emerging therapies further.
https://www.delveinsight.com/sample-request/chemotherapy-induced-nausea-and-vomiting-pipeline-insight?utm_source=sites&utm_medium=promotion&utm_campaign=kkpr

Leading Companies in the Chemotherapy-Induced Nausea and Vomiting Therapeutics Market Include:
Major firms advancing Chemotherapy-Induced Nausea and Vomiting therapies are - Helsinn Healthcare SA, Acacia Pharma, Camurus, Benuvia Therapeutics, Aphios Corporation, Zhuhai Beihai Biotech Co., Ltd., and others.

Chemotherapy-Induced Nausea and Vomiting Pipeline Analysis:
The Chemotherapy-Induced Nausea and Vomiting pipeline report offers insights into:

• Detailed information on companies creating therapies for Chemotherapy-Induced Nausea and Vomiting, including the total therapies per company.

• Various therapeutic candidates divided into early, mid, and late development stages for Chemotherapy-Induced Nausea and Vomiting treatment.

• Chemotherapy-Induced Nausea and Vomiting key players engaged in targeted therapy development, with active and inactive (dormant or halted) projects.

• Chemotherapy-Induced Nausea and Vomiting drugs in development, categorized by development stage, administration route, target receptor, monotherapy or combination approach, distinct mechanisms of action, and molecular type.

• In-depth review of partnerships (corporate-corporate and corporate-academic), licensing deals, and funding details to support future growth in the Chemotherapy-Induced Nausea and Vomiting market.

• The report draws from data sourced from proprietary databases, company/university sites, clinical trial databases, conferences, SEC documents, investor materials, and press releases from companies, universities, and industry-specific third parties.

Download a Sample PDF Report for more on Chemotherapy-Induced Nausea and Vomiting drugs and therapies.
https://www.delveinsight.com/sample-request/chemotherapy-induced-nausea-and-vomiting-pipeline-insight?utm_source=sites&utm_medium=promotion&utm_campaign=kkpr

Chemotherapy-Induced Nausea and Vomiting Pipeline Market Drivers

• Rising cancer incidence, unmet healthcare demands, emphasis on patient-focused care, technological innovations, regulatory encouragements, and other key elements are propelling the Chemotherapy-Induced Nausea and Vomiting Market.

Chemotherapy-Induced Nausea and Vomiting Pipeline Market Barriers

• Nevertheless, intricate causes, inconsistent patient reactions, side effects, difficulties in trial design, rivalry from current treatments, reimbursement issues, and other challenges are hindering growth in the Chemotherapy-Induced Nausea and Vomiting Market.

Scope of Chemotherapy-Induced Nausea and Vomiting Pipeline Drug Insight

• Coverage: Global

• Key Chemotherapy-Induced Nausea and Vomiting Companies: RedHill Biopharma, Acacia Pharma, Simon Williamson Clinic, Xiamen LP Pharmaceutical, Helsinn Healthcare SA, Heron Therapeutics, and others

• Key Chemotherapy-Induced Nausea and Vomiting Therapies: RHB-102, APD403, Akynzeo, IV Palonosetron 0.25 mg, NEPA (300mg netupitant/0.5mg palonosetron), SUSTOL, and others

• Chemotherapy-Induced Nausea and Vomiting Therapeutic Assessment: Current marketed and emerging Chemotherapy-Induced Nausea and Vomiting therapies

• Chemotherapy-Induced Nausea and Vomiting Market Dynamics: Drivers and barriers in the Chemotherapy-Induced Nausea and Vomiting market

About DelveInsight
DelveInsight is a premier Business Consultant and Market Research firm specializing in life sciences. It assists Pharma companies with holistic solutions to enhance performance. It also provides Healthcare Consulting Services, aiding in market analysis to boost business expansion and tackle challenges effectively.

Contact Us:
Kanishk

kkumar@delveinsight.com